Nonetheless, while tocilizumab demonstrates efficacy in managing CRS, IL-6 blockade does not consistently prevent ICANS development and its impact on ICANS remains limited in most cases [6, 10, 16]. Here, IL6 is linked to congenital rubella syndrome.